Drug Database
Back to search

Poland· PL-100397490

Mitoxantron Sandoz

A mitoxantrone product containing mitoxantronum, registered in Poland by Sandoz GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC L01DB07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedMitoxantron SandozATCL01DB07REGISTER NO.PL-100397490PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mitoxantronumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mitoxantrone is registered in 14 of 19 countries.

Countries holding a registration under ATC L01DB07 (mitoxantrone), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search mitoxantrone products by name

Mitoxantrone · ATC L01DB07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Mitoxantronum
Manufacturer
Sandoz GmbH
Country
Poland (PL)
ATC code
L01DB07
ATC class
Mitoxantrone
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991368111
  • gtin
    05909991368128

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

405 interactions on record for mitoxantrone.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check mitoxantrone against other medicinesHow interaction checks work

Mitoxantrone · interactions on record

405 records

  • 31 severe
  • 199 moderate
  • 15 minor
  • 160 info

Most severe, free to view

  • DolasetronA04AA04severe
  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Mitoxantrone in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mitoxantrone products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Ebexantron
  • Belgium · Mitoxantrone Sandoz
  • Bulgaria · Митоксантрон Ебеве
  • Germany · Mitoxantron Hexal, Novantron
  • Denmark · Mitoxantron "ebewe"
  • Estonia · Onkotrone
  • Spain · Mitoxantrona Accord, Novantrone
  • Finland · Mitoxantron Ebewe
  • France · Mitoxantrone Accord
  • United Kingdom (Northern Ireland) · Mitoxantrone Accord Healthcare, Onkotrone Injection
  • Greece · Mitoxan
  • Hungary · Onkotrone
  • Italy · Onkotrone
  • Lithuania · Onkotrone
  • Luxembourg · Mitoxantrone Sandoz
  • Latvia · Onkotrone
  • Malta · Onkotrone
  • Netherlands · Mitoxantron Accord, Mitoxantron Sandoz
  • Norway · Mitoxantron Ebewe
  • Portugal · Mitoxantrona Pharmis, Mitoxantrone Baxter
  • Romania · Onkotrone
  • Sweden · Mitoxantron Ebewe
  • Slovenia · Onkotrone
  • Slovakia · Onkotrone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/102bc4bd-891d-403e-8f48-fd0cd25b6fe0
GET /v1/drugs/102bc4bd-891d-403e-8f48-fd0cd25b6fe0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "2 mg/ml",
  "packaging": "05909991368111 ¦ Rpz ¦ 127472\n1 fiol. 5 ml\n05909991368128 ¦ Rpz ¦ 127473\n1 fiol. 10 ml",
  "substance": "Mitoxantronum 20mg/10 ml",
  "common_name": "Mitoxantronum",
  "pl_product_id": "100397490",
  "pozwolenie_nr": "24649",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about mitoxantrone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console